Vascular remodeling may be a mechanism linking chronic kidney disease to cardiovascular disease. Whether early kidney dysfunction is associated with small and large arterial remodeling is not well understood. Using multivariable linear regression, back-transforming beta-coefficients to relative difference, the authors studied the association of cystatin C, creatinine-based estimated glomerular filtration rate (GFR), and albuminuria with small (SAE) and large (LAE) arterial elasticity and aortic distensibility among 6,282 participants in the Multiethnic Study of Atherosclerosis at baseline (2000)(2001)(2002). Compared with the lowest quintile, higher quintiles of cystatin C were incrementally associated with lower SAE: third quintile relative difference ¼ À5% (95% confidence interval (CI): À8, À2); fourth quintile relative difference ¼ À10% (95% CI: À13, À8); and highest quintile relative difference ¼ À16% (95% CI: À20, À12). By use of creatinine, the association was observed only among those with chronic kidney disease (estimated GFR, <60 mL/minute/1.73 m 2 ): relative difference ¼ À9% (95% CI: À13, À4). Albuminuria was significantly associated with lower SAE: relative difference ¼ À6% (95% CI: À10, À1). Cystatin C was associated with lower LAE only at the highest quintile (relative difference ¼ À3%, 95% CI: À6, 0) compared with the lowest quintile. By use of creatinine, chronic kidney disease was not independently associated with LAE (P ¼ 0.912). Cystatin C, estimated GFR, and albuminuria were not associated with aortic distensibility (P ¼ 0.26, 0.48, 0.45). Early kidney dysfunction is significantly associated with decreased arterial elasticity in smaller arteries and, to a lesser degree, in larger arteries.
at a GFR level above 60 mL/minute (16, 17) . Prior studies have also been somewhat limited by small sample sizes, select populations, and a lack of ethnic diversity. In addition, whether the association between kidney dysfunction and arterial stiffness differs by caliber of vessel remains unclear (11, 12) . Moreover, none of the studies has evaluated the association of kidney dysfunction across the full spectrum with arterial functional changes (elasticity).
This analysis explores the association of kidney function measures with 1) small and large arterial elasticity measured by pulse waveform analysis and 2) aortic distensibility measured by magnetic resonance imaging in a large, multiethnic cohort. We hypothesized that early kidney dysfunction would have an independent association with decreased arterial elasticity and that this association would be stronger for small arteries because small renal vascular beds appear to be more sensitive to increased pulsatile stress (18) , and their remodeling may be present at earlier stages of disease.
MATERIALS AND METHODS

Subjects
The Multiethnic Study of Atherosclerosis (MESA) is a large study sponsored by the National Heart, Lung, and Blood Institute aimed to improve understanding of subclinical cardiovascular disease and its progression in a multiethnic cohort. Details on recruitment and design have been published previously (19) . Briefly, MESA recruited 6,814 men and women who were aged between 45 and 84 years, were free of cardiovascular disease, and self identified as white, African American, Hispanic, or Chinese American. Subjects were recruited from Baltimore City and Baltimore County, Maryland; Chicago, Illinois; Forsyth County, North Carolina; Los Angeles County, California; northern Manhattan and the Bronx, New York; and St. Paul, Minnesota, between July 2000 and August 2002. Individuals were excluded from this study if they had physiciandiagnosed heart attack, angina, heart failure, stroke or transient ischemic attack, or atrial fibrillation; if they had undergone coronary artery bypass grafting, angioplasty, valve replacement, or pacemaker insertion; or if they weighed >300 pounds (>136.08 kg). The institutional review boards at all participating centers approved the study, and all participants gave informed consent. We used data from the baseline visit from July 2000 to July 2002. Among the 6,814 participants, 532 had either no pulse-wave measures, cystatin C, or creatinine and therefore were excluded, leaving 6,282 participants for these analyses.
Primary outcomes measures
Large and small artery elasticity indices (in mL/mm Hg) were measured by the PulseWave CR-2000 Research CardioVascular Profiling Instrument (Hypertension Diagnostics, Inc., Eagan, Minnesota) to acquire and analyze pulse waveforms from the radial artery. The PulseWave CR-2000 obtains blood pressure measurements and arterial pulse waveforms with an oscillometric blood pressure module and an arterial pulse pressure sensor. While the participant was supine, the pulse pressure sensor was positioned on the right wrist, supported by a wrist stabilizer, and measurements were taken for 30 seconds. A blood pressure cuff was placed on the contralateral arm. By using the pulse contour analysis technique, both large and small arterial characteristics were studied. By incorporating pressure fluctuations, this method provides a way to study changes in large and small arteries and their ability to withstand distending pressures throughout the cardiac cycle. Specifically, the first peak of the recorded wave represents large arteries as it results from the expansion of the arteries after systole. The second peak is a rebound wave, which mainly represents the elasticity in the smaller arteries. The estimation of elasticity was then performed by a computer-based, thirdorder, 4-element Windkessel model that analyzes the diastolic pulse contour and calculates an elasticity index for both small (C 2 ) and large (C 1 ) arteries. Briefly, this model divides total systemic arterial compliance into large artery (capacitive) or small artery (oscillatory) compliances and then incorporates other parameters (age, heart rate, ejection time, weight, and height) to estimate the elasticity index. Systemic vascular resistance is calculated by dividing the mean arterial pressure (estimated from the oscillometric cuff) by the cardiac output. Cardiac output (in L/minute) was calculated after directly measuring ejection time (in milliseconds) from the pulse waveform and including heart rate, height, age, and body surface area (mm 2 ). The use of noninvasive pulse-wave contour analysis measures has been described in detail previously, and these measures have been compared with invasive methods that have high degrees of correlation (20) . Moreover, this method has been shown to have high correlation in repeated measures (21, 22) .
The magnetic resonance imaging aortic distensibility index was calculated by use of measures of the ascending aorta obtained with 1.5-T Singa CV/I or Signa LX whole-body magnetic resonance imaging systems (General Electric Healthcare, Chalfont St. Giles, United Kingdom). Aortic wall measurements were determined by the Magnetic Resonance Analytical Software System 4.2 (Medis Medical Imaging Systems, Leiden, the Netherlands). A detailed description of the protocol has been published previously (23, 24) . Briefly, these measures were incorporated into the following equation to estimate aortic distensibility throughout the cardiac cycle: aortic distensibility ¼ ((maximum aortic cross-sectional area À minimum aortic cross-sectional area)/minimum area)/pulse pressure. The pulse pressure used was the average pulse pressure of the measures immediately before and after the magnetic resonance imaging examination.
Primary predictors
Kidney function was assessed by using cystatin C, the creatinine-based Modified Diet in Renal Disease estimated GFR (25) , and albuminuria. Blood was collected and stored at À70°F (21.11°C) until needed for the appropriate assays. Cystatin C was measured using a particle-enhanced immunonephelometric assay (N Latex Cystatin C; Dade Behring, Inc., Deerfield, Illinois) and categorized into quintiles. Creatinine was measured by rate reflectance spectrophotometry using a thin film adaptation of the creatine amidinohydrolase method on a Vitros analyzer (Johnson & Johnson Clinical Diagnostics, Inc., Rochester, New York) at the Collaborative Studies Clinical Laboratory at FairviewUniversity Medical Center (Minneapolis, Minnesota). We categorized the cohort into 3 mutually exclusive groups using both cystatin C and creatinine: Chronic kidney disease was defined as an estimated GFR of <60 mL/minute/1.73 m 2 ; preclinical kidney disease was defined as a GFR of !60 mL/minute/1.73 m 2 and cystatin C of !1.0 mg/L, and normal was defined as a GFR of !60 mL/minute/1.73 m 2 and cystatin C of <1.0 mg/L. We used these definitions because this ''preclinical'' stage of chronic kidney disease has been associated with increased risks of mortality, adverse cardiovascular outcomes, and incident chronic kidney disease (3). Urinary albumin and creatinine were measured by nephelometry and the Jaffe reaction rate, respectively. A urinary albumin:creatinine ratio was calculated, and a value of !30 mg/g was considered albuminuria.
Secondary predictors
Blood pressure measurements were obtained by using an automated blood pressure device (DINAMAP PRO 100 monitor; General Electric Healthcare), with the participant in the seated position after resting 5 minutes. Participants were instructed to fast and to refrain from exercise for 12 hours prior to the visit, as well as to refrain from smoking on the morning of the visit. Three sequential measures were obtained, and the average of the second and third measurements was recorded.
Information on self-reported race/ethnicity, level of education, annual household income, smoking history, and medication utilization was obtained by standardized questionnaires. Hypertension was defined as systolic pressure of !140 mm Hg, diastolic pressure of !90 mm Hg, or current use of antihypertensive medication. Diabetes was defined as fasting glucose of !126 mg/dL or the use of hypoglycemic medication or insulin. Cigarette smoking was defined as current, former, or never. Height and weight were measured with participants wearing light clothing and no shoes. Body mass index was calculated as weight (kg)/height (m) 2 . Fasting blood was collected and stored at À70°F (21.11°C) until needed for the appropriate assays, including high density lipoprotein cholesterol, triglycerides, glucose, interleukin-6, and C-reactive protein. Low density lipoprotein cholesterol was calculated by using the Friedewald equation.
Statistical analysis
We compared sociodemographic, anthropometric, and biologic characteristics by quintile of cystatin C using analysis of variance for continuous variables or the chi-squared test for categorical variables. Using multivariable linear regression with adjustment for relevant covariates, we studied the association of early kidney dysfunction with small or large arterial elasticity indices and magnetic resonance imaging aortic distensibility measures in separate models. We log transformed small and large elasticity indices because of their skewed distribution. We used nested models with the first model adjusted for sociodemographic variables: age, gender, self-reported race/ethnicity, income, education, and occupation. The second model adjusted for smoking, diabetes, and hypertension; low and high density lipoprotein cholesterol, triglycerides, fasting insulin, fasting glucose, interleukin-6, C-reactive protein, body mass index, and systolic and diastolic blood pressure levels; use of antihypertensive medication; use of lipid-lowering medications; and clinical site in addition to the sociodemographic variables in model 1. Variables were dropped from the final model if they failed to change the coefficient of cystatin C by 5% or more. The same covariates were used for estimated GFR and albuminuria and for analyses using normal, preclinical kidney disease (defined as GFR of !60 mL/minute/1.73 m 2 and cystatin C of !1.0 mg/L), and chronic kidney disease (defined as GFR of <60 mL/minute/1.73 m 2 ). In order to understand the magnitude of associations for small and large arterial elasticity, we then back transformed the beta coefficients in order to represent a relative difference. This coefficient represents the relative difference in small or large arterial elasticity per increment in kidney function estimate from a linear regression with ln(elasticity) as the dependent variable. For example, a relative difference of 0.95 represents a 5% decrease, whereas a relative difference of 1.50 represents a 50% increase.
We tested for interactions of kidney function with race, diabetes, hypertension, and use of angiotensin-converting enzyme I/angiotensin II receptor blocker and diuretics. All calculations were performed in S-PLUS, release 6.1, software (Insightful Corporation, Seattle, Washington) and SPSS, release 15.0.1.1, statistical software (SPSS, Inc., Chicago, Illinois); P < 0.05 was considered significant.
Because of the fact that the estimates of large arterial elasticity (LAE) and small arterial elasticity (SAE) by pulse-wave contour analysis include several physical measures that may be associated with kidney function, we also conducted 2 separate sensitivity analyses. In the first sensitivity analysis, we adjusted for the parameters that are included in the model (age, height, weight, systolic blood pressure, diastolic blood pressure, and heart rate).
In the second sensitivity analysis, we used the product of SAE 3 system vascular resistance (SVR) or LAE 3 SVR as our outcome. The rationale for this analytical method is that the physical measures enter estimation of LAE and SAE primarily through estimation of SVR, so the products of LAE 3 SVR and SAE 3 SVR reflect mainly the information in the pulse waveform.
RESULTS
Participants' characteristics
Among the 6,282 participants in this study, the mean age was 62 (standard deviation, 10) years, 52% were female, 45% were hypertensive, and 14% were diabetic. Thirtyeight percent were white, 12% Chinese, 27% African American, and 23% Hispanic. Approximately 9% of the cohort had an estimated GFR of <60 mL/minute/1.73 m 2 , 7% had an estimated GFR of 45-59 mL/minute/1.73 m 2 , and only 1% and 0.3% had estimated GFR values of 30-44 and <30 mL/minute/1.73 m 2 , respectively. Approximately 9% of participants had albuminuria. Approximately 16% of participants had preclinical chronic kidney disease (estimated GFR (Modified Diet in Renal Disease), !60 mL/ minute/1.73 m 2 ; cystatin C, !1 mg/L). Characteristics of participants by quintiles of cystatin C are described in Table 1 . Participants in the highest quintile of cystatin C were older, had lower socioeconomic status, and were more likely to be hypertensive and diabetic.
Kidney dysfunction and small arterial elasticity Cystatin C was significantly and incrementally associated with lower small arterial elasticity after full adjustment. This association was significant even at the third quintile of cystatin C and strengthened incrementally with higher quintiles of cystatin C ( Table 2 ). These findings were unchanged in both magnitude and significance after adjustment for albuminuria: Relative differences were À5% (95% confidence interval (CI): À8, À2) for the third quintile of cystatin C, À10% (95% CI: À13, À8) for the fourth quintile, and À16% (95% CI: À20, À12) for the highest quintile compared with the lowest quintile of cystatin C. Creatinine-based estimated GFR was associated with lower small arterial elasticity only at an estimated GFR of <60 mL/minute/1.73 m 2 in unadjusted and adjusted models. Similarly to cystatin C, adjustment for age and sociodemographic factors did not significantly attenuate this association, but it was diminished by adjustment for comorbidities, medication use, and inflammatory markers ( Table 2 ). An estimated GFR of 45-59 mL/minute/1.73 m 2 was also associated with small arterial elasticity (relative difference ¼ À9%, 95% CI: À14, À5). The presence of albuminuria was also significantly associated with lower small arterial elasticity after multivariate analysis (Table 2) .
Compared with normal kidney function (estimated GFR, !60 mL/minute/1.73 m 2 ; cystatin C, <1.00 mg/L), both preclinical kidney disease and chronic kidney disease were associated with significantly lower small arterial elasticity in fully adjusted models (Table 2) .
There was no interaction of race/ethnicity with cystatin C for small arterial elasticity (P ¼ 0.60). Within each race/ ethnicity stratum, the highest quintile of cystatin C was significantly associated with reduced small arterial elasticity: relative difference ¼ À17% (95% CI: À23, À11) in whites; relative difference ¼ À14% (95% CI: À25, À1) in Chinese; relative difference ¼ À13% (95% CI: À20, À7) in blacks; and relative difference ¼ À18% (95% CI: À25, À10) in Hispanics. There were no significant interactions with the use of angiotensin-converting enzyme I/angiotensin II receptor blocker or diuretics (P ¼ 0.88), or diabetes (P ¼ 0.69), for small artery elasticity. The association between cystatin C and lower small arterial elasticity was somewhat stronger among those without hypertension, but this interaction was not statistically significant (P interaction ¼ 0.06).
Kidney dysfunction and large arterial elasticity
Cystatin C was associated with lower large arterial elasticity from the third quintile of cystatin C in unadjusted analyses. After adjustment, this association was significant only at the highest quintile (cystatin C, >1.02 mg/L). Chronic kidney disease (estimated GFR, <60 mL/minute/ 1.73 m 2 ) was associated with lower large arterial elasticity in unadjusted models, but this association was not significant after adjustment for age and sociodemographic factors. Large arterial elasticity was not associated with estimated GFR of 45-59 mL/minute/1.73 m 2 (relative difference ¼ 0%, 95% CI: 2, 4). These findings were not altered after adjustment for albuminuria. Albuminuria was significantly associated with lower large arterial elasticity in all models, although it was attenuated by each stage of adjustment ( Table 3) .
In unadjusted analysis, large arterial elasticity was lower among those with preclinical kidney disease (median, 11.64 mL/mm Hg 3 10) and chronic kidney disease (median, 10.18 mL/mm Hg 3 10) compared with those with no chronic kidney disease (12.95 mL/mm Hg 3 10). However, after age and demographic adjustment, these associations were attenuated (Table 3) .
We found no interactions in these associations for race/ ethnicity, diabetes, use of angiotensin-converting enzyme I/angiotensin II receptor blocker or diuretics, or hypertension (P ¼ 0.17, 0.46, 0.30, and 0.80, respectively).
Sensitivity analyses for SAE and LAE
Adjustment for age, heart rate, height, weight, systolic blood pressure, and diastolic blood pressure did not materially change the findings. Cystatin C was significantly and incrementally associated with lower small arterial elasticity starting at the third quintile of cystatin C. Similarly, the association with LAE was significant only at the highest quintile (cystatin C, >1.02 mg/L). When we used the product SAE 3 SVR or LAE 3 SVR, the results were also not materially different.
Kidney dysfunction and magnetic resonance imaging aortic distensibility
All 4 quintiles of cystatin C were associated with lower aortic distensibility in unadjusted models. However, after adjustment for age and sociodemographics, these associations were no longer significant. Similarly, chronic kidney disease and albuminuria were associated with lower aortic distensibility in unadjusted analyses but not after multivariable adjustment (Table 4) . Estimated GFR of 45-59 mL/minute/1.73 m 2 was not associated with aortic distensibility (b ¼ 0.07, 95% CI: À0.1, 0.23).
DISCUSSION
In a large, multiethnic cohort free of cardiovascular disease, we found that the association of kidney dysfunction with decreased arterial elasticity varied greatly by vessel caliber. Cystatin C had significant inverse associations with small arterial elasticity across its distribution. However, only the highest quintile of cystatin C was associated with lower large artery elasticity. Cystatin C was not independently associated with aortic distensibility. Creatinine-based Kidney Dysfunction and Arterial Elasticity 743 estimated GFR of <60 mL/minute/1.73 m 2 was associated with lower small arterial elasticity but not with large artery elasticity or aortic distensibility. Our findings suggest that vascular remodeling of the small arteries is present in early stages of kidney dysfunction, whereas changes in the large arteries appear later in the progression of the disease. These (17) 168 (13) 124 (10) 142 (11) 98 (8) African American 406 (30) 362 (28) 308 (26) 303 (24) 328 (28) Hispanic 271 (20) 308 (24) 285 (24) 311 (24) 244 (21) Education, no. (%) <0.001
Less than high school 217 (16) 215 (17) 210 (17) 249 (20) 250 (21) High school or certificate 576 (43) 572 (45) 585 (49) 585 (46) 605 (51) College graduate 547 (41) 484 (38) 411 (34) 438 (34) 323 (27) Income, no. (%) <0.001 <$20,000 238 (18) 275 (22) 252 (22) 319 (26) 357 (32) $20,000-$39,999 357 (27) 293 (24) 299 (26) 318 (26) 345 (31) $40,000-$74,999 353 (27) 371 (30) 334 (29) 305 (25) 255 (23) !$75,000 364 (28) 295 (24) 277 (24) 277 (23) 158 (14) Smoking, no. (%) <0.001
Current 146 (11) 163 (13) 164 (14) 157 (12) 170 (14) Mean body mass index, kg/m 2 (SD) 27 (5) 28 (5) 28 (5) 29 (6) 55 (16) 51 (14) 51 (14) 48 (14) 48 (14) <0.001
Medication use ACE inhibitors (without diuretics), no. (%)
107 (8) 110 (9) 120 (10) 162 (13) 245 (21) <0.001
ARBs (without diuretics), no. (%)
31 (2) 36 (3) 40 (3) 48 (4) 64 (5) <0.001
Diuretics, no. (%) 87 (7) 120 (9) 137 (11) 189 (15) findings may have important implications for elucidating mechanisms to explain the link between chronic kidney disease and cardiovascular disease.
Our findings add to previous research linking chronic kidney disease to arterial stiffness measured by pulse-wave velocity (10) (11) (12) (13) (14) (15) . In addition, our findings are consistent with data suggesting regional vascular differences in the association of chronic kidney disease and arterial stiffness among hypertensives and diabetics (11, 12) . Prior studies have been limited to studying moderate to severe kidney dysfunction because creatinine-based measures are known to be imprecise at an estimated GFR of !60 mL/minute (17) . Therefore, the associations of kidney dysfunction with vascular stiffness at GFR of !60 mL/minute have not been well evaluated. Moreover, comparisons of the associations of kidney dysfunction across different-caliber vessels or functional measures of vessel elasticity have not been well described. Prior studies had limitations of small sample sizes, lack of diversity, and select cohorts of diabetics or hypertensives that may have limited generalizability (10) (11) (12) (13) (14) (15) .
These findings are of potential importance in elucidating mechanisms that may explain the association of chronic kidney disease and preclinical stages of chronic kidney disease and cardiovascular disease (1, 3) . Our study may provide some insights into the effects of impaired kidney function on the vasculature. Although our study is crosssectional and, therefore, cannot determine temporal or causal relations, it is possible that arterial remodeling among subjects with kidney dysfunction may begin with small vessels and expand to larger arteries as kidney disease progresses (11, 14) . Many mechanisms may be responsible for the remodeling of arteries that occur in persons with chronic kidney disease. Kidney microvasculature may be particularly susceptible to changes in pressures from upstream arteries (18) . In persons with chronic kidney disease, changes in calcium-phosphate products and oxidative stress have been postulated as potential mechanisms for increased stiffness (26) , as have alterations in the renin-angiotensin system (13). Even small decreases in kidney function may lead to hypertrophy and sclerosis of the microvasculature and the glomerulus, and these changes may lead to increased cardiac workload during both systole and diastole phases (11) . Such mechanisms could explain the association between mildly impaired kidney function and elevation in heart failure risk (27) . As the effects of kidney disease on larger vessels appear to develop more slowly, other mechanisms may be more important, such as more deposition of glycation products (28) . We found no associations between kidney dysfunction and large arterial elasticity or magnetic resonance imaging aortic distensibility. This may be due to the fact that our cohort has fewer participants who are elderly, none had known cardiovascular disease, and few had advanced chronic kidney disease, thus possibly limiting our ability to detect these associations. Moreover, prior literature had studied these associations among diabetics and hypertensives, populations that may have abnormal vasculature independent of GFR.
Our study is novel in that it used a functional measure of arterial properties by using pulse-wave contour analysis to determine large and small artery elasticity indices. This method makes certain assumptions about the arterial tree when using the Windkessel model of the circulation. Some studies have suggested low reliability of the C 1 and C 2 estimates, which may reduce the validity of the methodology (29) . However, pulse-wave contour analysis highly correlates with invasive measures of arterial compliance, and it has high reproducibility (20) (21) (22) . This method has been used to detect early stages of vascular changes in young individuals free of cardiovascular disease (30) , as well as vascular changes in individuals with hypertension, diabetes (20) , and peripheral vascular disease (31) . Although data on the prognostic value of C 1 and C 2 are still under investigation, small arterial elasticity estimated by this methodology has been shown to predict cardiovascular events (32) .
Our study is limited by its cross-sectional design. Therefore, the direction of the associations cannot be determined. Reductions in small arterial elasticity may be a determinant of kidney disease, the processes could develop in parallel, or renal dysfunction could lead to arterial stiffening. Our results may also be confounded by the effect of increased effective arterial volume in subjects with chronic kidney disease. However, our results are robust even at very early stages of kidney dysfunction, making this less likely. In addition, our cohort does not include participants with cardiovascular disease where arterial stiffness and chronic kidney disease are more prevalent. There may still be residual confounding from variables not measured in our study. We did not have enough power to test associations at more advanced stages of chronic kidney disease in this cohort (estimated GFR, <45 mL/ minute/1.73 m 2 ). In addition, we did not directly measure GFR, thus limiting the precision of our estimates of kidney function.
We found that early, preclinical stages of kidney dysfunction and chronic kidney disease were associated with decreased arterial elasticity and that these associations varied significantly by vessel caliber. Given the increased risk of cardiovascular disease among those with preclinical and clinical chronic kidney disease, this may represent a pathway to explain the cardiovascular and heart failure risk associated with kidney disease. In particular, the strong association of small arterial elasticity with preclinical chronic kidney disease is of particular interest given the increased risk of adverse cardiovascular outcomes and chronic kidney disease in this population. Future studies should focus on longitudinal measures to understand whether arterial remodeling, particularly of the small arteries, predicts the progression from preclinical kidney disease to chronic kidney disease and whether this remodeling may be associated with the increased cardiovascular risk among persons with early kidney dysfunction.
